Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis

By sjmartinez • November 2, 2024

Warren RB, Donnelly K, Kiri S, Taieb V, Slim M, Fahrbach K, Neupane B, Betts M, Armstrong A. Long-Term Efficacy and Safety of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: Updated Systematic Literature Review and Network Meta-analysis. Dermatol Ther (Heidelb). 2024 Nov 1. doi: 10.1007/s13555-024-01302-0. Epub ahead of print. PMID: 39485596.

Tags: adalimumab, bimekizumab, Dermatology, guselkumab, Long-term efficacy, Long-term safety, Network meta-analysis, psoriasis, Publications, risankizumab, secukinumab, ustekinumab

Joint Position Statement from the National Psoriasis Foundation Medical Board and the International Psoriasis Council on Routine Testing for Latent Tuberculosis Infection Prior To and During Treatment of Psoriasis Patients with IL-17 or IL-23 Inhibitors

Blauvelt A, Strober BE, Eakin GS, McCormick Howard L, Langan C, van de Kerkhof PCM, Puig L, Lebwohl MG, Romiti R, Armstrong AW, Choon SE,[...]

Matching-Adjusted Indirect Comparison of the Efficacy of Delgocitinib Cream and Dupilumab in the Treatment of Moderate to Severe Atopic Hand Eczema

Cohen D, Bewley A, Wollenberg A, Hong HC, Armstrong A, Jonsen E, Maslin D, Thoning H, von Eyben R, Chovatiya R. Matching-Adjusted Indirect Comparison of[...]

Novel Taxol-Derivative, STO-1, Induces Selective Anti-Tumor Immunity and Sustained Remission of Glioblastoma Without Triggering Autoimmune Reactions

Mohapatra S, Guerrero A, Rahman N, Zaman KT, Wu J, Onyeagba C, Hu C, Pellegrini M, Vankudoth J, Kitamura S, O'Donnell L, Wadghiri YZ, Banerjee[...]